Magnesium Sulphate for the Prevention of Super Ventricular Dysrrhythmias following Non-Cardiac Thoracic Surgery - MgSO for the prevention of SVD following non-cardiac thoracic surgery

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-002818-11-GB

Enrollment

200

Registered

2005-08-31

Start date

2004-12-08

Completion date

Unknown

Last updated

2012-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Thoracotomy Super Ventricular Dysrhythmias

Interventions

Trade Name: Magnesium Sulphate 50% Product Name: Magnesium Sulphate 50% w/v Pharmaceutical Form: Solution for infusion INN or Proposed INN: Magnesium Sulphate Concentration unit: mmol/ml millimole(s)/

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient having thoractomy for lobectomy, biloectomy, pneumonectomy or oesophagectomy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Renal impairment (creatinine >130) Pre-existing SVD Hypersensitivity to magnesium sulphate, if on antiarhythmics

Design outcomes

Primary

Measure	Time frame
Main Objective: Does the peri-operative administration of IV magnesium sulphate to coorrect hypomagnesaemia decrease the incidence of postoperative super ventricular dysrhythmias?;Secondary Objective: Does this improve mortality from thoractomy for lung resections or oesophagectomy?;Primary end point(s): Incidence of post thoratomy SVD	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026